Showing Blog Entries: 110 of 25

MA Appellate Practice and Procedure Bulletin - February 2021

Feb 2 2021
Boston Partner Tory A. Weigand comments on the Supreme Judicial Court’s recent decision in Dunn v. Genzyme (January 29, 2021) where the High Court addressed the conflict and differing views as to the level of specificity needed to plead state law product liability claims as to a FDA approved medical device in order to survive a motion to dismiss based on federal preemption and the plausibility standard under Rule 12(b)(6).

More Info